This content was supplied by our valued media partner; incathlab To view this interesting webinar on the management of the COVID-19 pandemic for cardiologists, please click the link below: https://www.incathlab.com/en/lives/16-others/67-others/2525-how-to-manage-cardiac-patients-during-the-covid-19-period Program Compare and discuss the different cardiac department organizations across Europe to face COVID-19 pandemic Italy – Gabriele Gasparini Spain – Javier Escaned France – Thierry Lefèvre […]
Chairpersons: Christopher Paul Cannon (Boston, United States of America), Dominick Joseph Angiolillo (Jacksonville, United States of America) Subtitle: Sponsored by Boehringer Ingelheim Learning Objectives: To review how the presentation of the RE-LY results 10 years ago heralded a decade of innovation in the non-Vitamin K antagonist oral anticoagulant (NOAC) treatment landscape – To assess the […]
Congress Presentation presented at AHA 2017 given by Dr. Chris Cannon with slides on a neutral background ( only Study branding) Including Q&A with Dr. Cannon and Dr. Hohnloser on FAQs related to the study results as well as the clinical implications of the results. Q&A 1: What may be the implication of the RE-DUAL […]
Dr Narbeh Melikian explains what intervention cardiology is when compared to traditional cardiology
Why do heart doctors care so much about your legs? How can a cardiologist care for your whole body? What is an interventional cardiologist in the first place? In this video, Dr. Daniel Ice, MD answers all of these questions and more.
Animated infographic Video summarizing the RE-DUAL PCI Results of different subgroups like ACS / non ACS, Ticagrelor vs Clopidogrel, Renal Function in less than three minutes.
Safety of uninterrupted dabigatran for cardiovascular interventions in the GLORIA-AF Registry Program (summarized by Prof Gregory Lip). An educational video summarizing data presented at EHRA, Barcelona 2018.
Animated infographic Video summarizing the RE-DUAL PCI Results published in NEJM comprehensively in two minutes.
Dual Antithrombotic Therapy with Dabigatran in AF Patients post PCI – Expert Interview with Dr. Jur ten Berg
Expert interview with Dr. Jur ten Berg about dual antithrombotic therapy with Dabigatran in AF patients post PCI. In the interview he focuses mainly on new subanalyses, presented at ACC Does the Discontinuation of ASA in the Warfarin-TT Arm Influence the Treatment Outcomes Vs Dabigatran-DT? Landmark analysis What treatment regimens were compared in the RE-DUAL […]
Interview series with Professor Stefan Hohnloser about dual antithrombotic therapy with Dabigatran in AF patients post PCI Should dabigatran dual therapy be the default strategy for most patients with AF and ACS? Which dabigatran dose would be recommended for patients with AF and ACS Post-PCI? How do the data reported on concomitant use of ticagrelor […]
Dr. Dominick Angiolillo summarizes the results of the RE-DUAL PCI study showing the safety of dabigatran dual therapy post-PCI with doses approved for stroke prevention in AF. He also shows data on subgroup analysis in patients with ACS / no ACS as an index event and subgroup analysis looking at results dependent on the P2Y12 […]